New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 7, 2014
08:29 EDTPPHMPeregrine reports supporting data for combining bavituximab with irradiation
Peregrine Pharmaceuticals announced data from studies demonstrating that an equivalent antibody to Peregrine's lead immunotherapeutic antibody candidate bavituximab administered with stereotactic body radiation therapy, or SBRT, showed a 100% improvement in survival and favorable tumor eradication in a model of non-small cell lung cancer, or NSCLC, compared to irradiation alone. These data were presented yesterday at the 105th Annual Meeting of the American Association for Cancer Research, or AACR, being held in San Diego, California from April 5-9, 2014. Bavituximab is an investigational immunotherapy currently being evaluated in NSCLC as part of the SUNRISE pivotal Phase III clinical trial.
News For PPHM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 13, 2015
17:19 EDTPPHMPeregrine to highlight Bavituximab at ASCO annual meeting
Peregrine Pharmaceuticals, a biopharmaceutical company focused on advancing bavituximab, a novel immuno-oncology agent in Phase III development, announced the presentation of three posters at the 2015 American Society of Clinical Oncology, ASCO, Annual Meeting, to be held May 29-June 2 in Chicago, Illinois.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use